知镜 Cognispect · 医学文献与研究工作台

Antimicrobial therapy against carbapenemase-producing bacteria: why MIC alone is not enough.

Rodríguez A, Claverias L, Canadell L, Picó-Plana E, Esteve-Pitarch E, Bodí M, Gómez-Bertomeu F.
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026-11-09 · PMID 43021620

文献摘要

Carbapenemase-producing Gram-negative bacteria represent a major therapeutic challenge in infectious diseases and critical care medicine. Although antimicrobial susceptibility testing remains fundamental, reliance on minimum inhibitory concentration alone is insufficient to predict clinical success. The efficacy of antimicrobial therapy is influenced by multiple factors, including the specific carbapenemase present, bacterial species-specific resistance mechanisms, infection site pharmacology, and pharmacokinetic/pharmacodynamic target attainment. Carbapenemases belonging to Ambler classes A, B, and D confer distinct susceptibility profiles that determine the activity of novel β-lactam/β-lactamase inhibitor combinations. Furthermore, co-resistance mechanisms such as porin mutations, efflux pump overexpression, and AmpC hyperproduction frequently modify antibiotic activity. These mechanisms are particularly relevant in pathogens such as Pseudomonas aeruginosa and Klebsiella pneumoniae . In critically ill patients, altered pharmacokinetics and impaired tissue penetration further complicate therapy. This review proposes a framework for antimicrobial selection against carbapenemase-producing organisms based on four key determinants: resistance mechanism, bacterial species, infection focus, and pharmacodynamic optimization.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。